Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C5252 in recurrent or progressive glioblastoma
NCT05095441Phase 1Not yet recruiting
- Sponsor
- ImmVira
- Start
- Mar 2023
- Primary completion
- Apr 2023
- Modality
- Gene Editing, Prophylactic Vaccines, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of MVR-C5252 in glioblastoma (GBM) (2 arms), sponsored by ImmVira. Primary endpoints: Evaluate the safety and tolerability of C5252 at 28 days, Characterize Dose Limiting Toxicities at 28 days and 1 more. Planned start Mar 2023; status: not yet recruiting.
02
Drugs
MVR-C5252
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT05095441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05095441.